

Unresolved alterations in bile acid composition and dyslipidemia in maternal and cord blood after ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy

Srijani Basu^{1,2,3} †, Sarah G. Običan^{4,5} †, Enrico Bertaggia^{1,6}, Hannah Staab¹, M. Concepcion Izquierdo^{1,6}, Cynthia Gyamfi-Bannerman⁴, Rebecca A. Haeusler^{1,2,3,6*}

¹Naomi Berrie Diabetes Center, Columbia University, New York, NY; ²Columbia University Digestive and Liver Disease Research Center, New York, NY; ³Department of Medicine, Columbia University, New York, NY;

⁴Department of Obstetrics and Gynecology, Columbia University, New York, NY; ⁵Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL; ⁶Department of Pathology and Cell Biology, Columbia University, New York, NY

† These authors contributed equally

*To whom correspondence should be addressed

Email: rah2130@cumc.columbia.edu

Running title: Bile acids and lipids in intrahepatic cholestasis of pregnancy

Abbreviations: ALT=alanine aminotransferase; BAs=bile acids; BMI=body mass index; BSEP=bile salt export pump, the canalicular BA efflux transporter; CA=cholic acid; CDCA=chenodeoxycholic acid; CE=cholesteryl ester; FC=free cholesterol; FPLC=fast protein liquid chromatography; GA=gestational age; HDL-C=high-density lipoprotein-cholesterol; ICP=intrahepatic cholestasis of pregnancy; ICP-diab=ICP plus diabetes; ICP-NoDiab=ICP without diabetes; LDL-C=low-density lipoprotein-cholesterol; NTCP=sodium-taurocholate cotransporting peptide, a sinusoidal BA uptake transporter; PL=phospholipid; TG=triglyceride; UDCA=ursodeoxycholic acid

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is characterized by elevated plasma bile acid levels. ICP is linked to adverse metabolic outcomes, including a reported increased risk of gestational diabetes. The standard therapeutic approach for managing ICP is treatment with ursodeoxycholic acid (UDCA) and induction of labor prior to 40 weeks of gestation. To investigate bile acid and metabolic parameters after UDCA treatment, we enrolled 12 ICP patients with singleton pregnancies—half with and half without gestational diabetes—and 7 controls. Our study reveals that after UDCA treatment, notwithstanding a reduction in total bile acid and ALT levels, imbalances persist in the cholic acid (CA) to chenodeoxycholic acid (CDCA) ratio in maternal and cord blood plasma. This indicates a continued dysregulation of bile acid metabolism despite therapeutic intervention. Maternal plasma lipid analysis showed a distinct maternal dyslipidemia pattern among ICP patients, marked by elevated cholesterol levels on VLDL particles and heightened triglyceride concentrations on LDL particles, persisting even after UDCA treatment. Cord plasma lipid profiles in ICP patients exhibited elevated triglyceride and free fatty acid levels alongside a tendency toward increased β -hydroxybutyrate. The changes in lipid metabolism in both maternal and cord blood correlated with the high CA/CDCA ratio, but not total bile acid levels or gestational diabetes status. Understanding the imbalances in maternal and cord bile acid and lipid profiles that persist after standard UDCA therapy provides insights for improving management strategies and mitigating the long-term consequences of ICP.

Keywords: Bile acids metabolism; Diseases; Dyslipidemias; Diabetes; Lipoproteins; Pregnancy

News and Noteworthy

This study uncovers that despite ursodeoxycholic acid treatment, intrahepatic cholestasis of pregnancy (ICP) is associated with increases in the ratio of cholic acid to chenodeoxycholic acid in both maternal and cord blood, suggesting ongoing dysregulation of bile acid metabolism. The high cholic to chenodeoxycholic acid ratio is correlated with maternal dyslipidemia and high cord blood lipids. These findings may inform more targeted approaches to managing ICP.

Introduction

Intrahepatic cholestasis of pregnancy (ICP) is a condition characterized by elevated plasma bile acids (BAs) and liver transaminases, maternal pruritus, and adverse pregnancy outcomes (1). Susceptibility to ICP is influenced by genetic variation (2–13) and steroid hormones, which inhibit BA transport through multiple mechanisms (14). The latter occurs to a mild extent in normal pregnancy (15–17), and there is evidence that maternal circulating BAs are subclinically elevated in normal pregnancy (14). In ICP, these effects may be exacerbated due to genetic variation in BA transporters (2–13), and due to increases in certain hormone products such as sulfated progesterone metabolites, which are elevated in ICP patients (18–20). These metabolites appear to be cholestatic due to a combination of multiple mechanisms: (i) they competitively inhibit BA binding and transport by Na⁺-taurocholate transporting polypeptide (NTCP), the sinusoidal uptake transporter for BAs (21); (ii) they can trans-inhibit the bile salt export pump (BSEP), the canalicular efflux transporter for BAs (22); and (iii) they also competitively inhibit BA binding and activation of the farnesoid X receptor (FXR), the BA-regulated nuclear receptor that transcriptionally induces hepatobiliary BA efflux (23).

In addition to high maternal serum BAs, there are other notable alterations in BAs during ICP. First, cord serum BAs are also elevated (24, 25). Second, there are characteristic alterations in BA composition. The most well-recognized change, which occurs in both maternal and cord serum, is an increase in the ratio of cholic acid (CA) to chenodeoxycholic acid (CDCA), the two primary BAs synthesized by the human liver (18, 24, 26–28).

The most common treatment for ICP is ursodeoxycholic acid (UDCA), which improves liver function tests and reduces pruritus (29). In some studies, UDCA also reduces maternal total BAs (24, 29), although this has not been observed in all trials (30, 31). UDCA has also been reported to partially reverse the qualitative changes in BA composition and maternal and cord serum (18, 24), though other reports indicate that UDCA does not restore cord BA composition (32).

ICP is also associated with alterations in maternal and fetal metabolic health: it has been reported that mothers with the condition are more likely to be diagnosed with gestational diabetes (33). They also show altered lipid profiles. Some reports show higher triglycerides, higher low-density lipoprotein cholesterol (LDL-C), and lower high-density

lipoprotein cholesterol (HDL-C) (34–38), although this has not been fully characterized using detailed lipoprotein fractionation methods. Other reports indicate that ICP, like other cholestatic conditions, results in the accumulation of Lipoprotein X (39, 40). Lipoprotein X has a similar density to LDL, but has a similar size to VLDL, and it is particularly rich in phospholipids and free cholesterol. Altered maternal lipids are known to be associated with adverse pregnancy outcomes (41). Children born to mothers with ICP have been reported to be more likely to have fetal growth abnormalities, including being born large for gestational age (42) or having fetal growth restriction (43, 44) and to show metabolic abnormalities during adolescence (45). In a mouse model of maternal hypercholanemia—wherein pregnant dams were fed a diet containing CA—female offspring were more susceptible to western diet-induced weight gain, glucose intolerance, and higher cholesterol in plasma and liver (45). This suggests metabolic reprogramming as a consequence of the *in utero* environment. However, fetal metabolic features during ICP, or ICP with gestational diabetes, are incompletely characterized.

BAs are known to regulate glucose and lipid metabolic parameters, through their physicochemical role in lipid absorption and through their ability to activate BA receptors such as FXR and TGR5 (46–48). BA signaling through FXR in the maternal liver and FXR in the placenta or fetal liver could potentially affect lipid metabolism in both mother and fetus. Moreover, data from preclinical models, and emerging genetic evidence in humans, suggest that BA composition—especially as it relates to cholic acid—also influences metabolic phenotypes (49, 50). However, the role of BA composition in the development of the metabolic effects of ICP are unknown. The aims of this study were to (i) characterize the maternal and cord blood metabolic features in UDCA-treated patients with ICP alone or both ICP and gestational diabetes; and (ii) determine the associations of these metabolic parameters with BA levels and BA composition.

Materials and methods

Subjects. We recruited 20 women pregnant with singletons: 7 ICP patients without diabetes (ICP-NoDiab) and 6 ICP patients with gestational diabetes (ICP-Diab), who had a scheduled delivery between 36 and 37 weeks (according to the clinical recommendations at the time of the study); and 7 control subjects without ICP, who were also scheduled to deliver in the same time frame. Women in the ICP-Diab group were diagnosed with gestational diabetes before the onset of cholestasis, and their diabetes care was managed by their physicians. The racial distribution of each group was: controls (3 white, 4 other), ICP-NoDiab (1 Asian, 3 white, 2 other), and ICP-Diab (1 Asian, 5 other). Ethnicity distribution was: controls (3 Hispanic, 3 Non-Hispanic, 1 other), ICP-NoDiab (4 Hispanic, 2 Non-Hispanic), ICP-Diab (5 Hispanic, 1 other). Exclusion criteria for recruitment included chronic hepatobiliary disease, multiple gestations, maternal systemic lupus erythematosus, and fetuses with identified heart block or suspected major congenital anomalies. One additional subject who had ICP without diabetes (patient #21) underwent our testing protocol, but was excluded from the group analyses, because she had previously undergone Roux-en-Y gastric bypass surgery, which is known to influence glucose and lipid metabolism (51), as well as BA levels and composition (52–56). We report the data from this subject in the online supplementary data (Supplementary Table S3). ICP was defined by pruritus and BAs $>10 \mu\text{mol/l}$. All ICP patients were prescribed UDCA by their physicians at the time of diagnosis. Fasting maternal blood was collected 3-5 days prior to delivery. Cord blood was collected at delivery. Body Mass Index (BMI) was available for women whose physicians had previously collected the information, early in the pregnancy. This study was approved by the institutional review board of Columbia University Medical Center and informed consent was received from all patients.

BA measurements. Fasting BA and alanine aminotransferase (ALT) measurements at the time of diagnosis were carried out by ARUP laboratories. For BA measurements in fasting maternal and cord plasma collected for full analysis, measurements were carried out at the Biomarkers Core Laboratory at Columbia's Irving Institute for Clinical and Translational Research. Briefly, 100 μl plasma was combined with 10 μl internal standard (cholate-d4 50nM, ISOTECH) and 1 ml ice-cold acetonitrile. Samples were vortexed, centrifuged for 15 minutes at 11,000xg, and supernatants were transferred to ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) vials. Samples were dried at 45° C under nitrogen, resuspended in 100 μl 55%/45% (v/v) methanol/ water (both with 5

mM ammonium formate). 5 μ l were injected into UPLC-MS/MS. Samples were compared against working standards of each BA species measured. BA levels are reported in μ mol/l.

Hormone and metabolite measurements. The fasting blood samples were also used to perform hormone and metabolite measurements. Plasma insulin and C-peptide were measured using ELISA kits (Merckodia), and glucose was analyzed with a hexokinase kit (Glucose HK, Sigma). Lipids were measured using colorimetric assays: triglycerides (Infinity, Thermo Scientific), free fatty acids, cholesterol, free cholesterol and phospholipids (Wako Diagnostics). Cholesteryl ester was calculated by subtracting free cholesterol from total cholesterol. β -Hydroxybutyrate and ALT were measured with assay kits (β -Hydroxybutyrate, Liquicolor Stanbio and ALT reagent, Teco Diagnostic). FGF19 was measured by ELISA (R&D Systems).

Lipoprotein fractionation. VLDL ($d < 1.006$ g/mL), LDL ($1.006 < d < 1.063$ g/mL) and HDL fractions ($1.063 < d < 1.210$ g/mL) were separated by sequential density ultracentrifugation, using the Optima MAX-TL Ultracentrifuge with TLA-100 rotor (Beckman Coulter). Fast protein liquid chromatography (FPLC) was carried out by running 200 μ l of plasma onto a Superose6 10/300 GL column (Amersham Pharmacia Biotech), and fractions were collected using the fraction collector FC-204 (Gilson). Fractions were analyzed with colorimetric kits as mentioned above.

Statistical analyses. All analyses were performed in the open source statistical package R. Data are reported as mean \pm standard error, or median [interquartile range], for normally or non-normally distributed data, respectively. For comparisons of non-normally distributed data between two groups, we used Mann-Whitney tests, or between three groups, we used Kruskal-Wallis and Dunn posthoc tests. For paired comparison before and after UDCA treatment, we used Wilcoxon signed rank test. Spearman rank correlations were calculated with non-transformed data.

Results

Subject characteristics. Data are shown in **Table 1**. There were no differences between groups in maternal age, gestational age at maternal blood collection, gestational age at delivery, or birthweight. Among the ICP patients, there was no effect of diabetes on gestational age at initiation of UDCA treatment, highest total BAs (as measured by ARUP clinical laboratories), or highest ALT. Seven ICP patients (3 ICP-NoDiab and 4 ICP-Diab) had highest total BAs above 40 $\mu\text{mol/l}$, which is considered severe ICP (57).

Maternal bile acid analysis. Total maternal fasting BAs were high at diagnosis and markedly decreased in most ICP patients after UDCA treatment (**Fig. 1A**), such that there were no significant differences in total BAs between UDCA-treated ICP patients and controls (**Fig. 1C**). These findings are consistent with the effect of UDCA to lower plasma BAs. Complete BA data is listed in **Supplementary Table S1**.

Next, we examined differences in BA composition between groups. Consistent with prior reports (18, 24, 26–28), we found that ICP patients had an increase in the ratio of CA to CDCA (including conjugated and unconjugated forms of each) (**Fig. 1D**). A depiction of the relative concentrations of individual BAs between groups is shown in **Supplementary Figure S1A**, and absolute values, median, and interquartile range are provided in **Supplementary Table S1**. These data suggest that in ICP patients, even after total BAs are normalized by UDCA treatment, the CA/CDCA ratio remains elevated.

As expected ALT was decreased by UDCA treatment (30), (**Fig. 1B**), such that at the time of maternal blood collection for full analyses, there were no differences between the groups (**Fig. 1E**). Next, we measured FGF19 as a marker of FXR activity. FXR regulates BA synthesis through the inhibitory action of FGF19 on the expression of the BA synthesis enzyme CYP7A1. FGF19 was highly variable and not significantly different between groups (median [interquartile range] for control and ICP, respectively, were 91.1 [81.9] and 53.4 [53.4] pg/ml, $P = 0.22$).

Cord bile acid analysis. We observed no significant difference in total BAs from cord blood plasma between the controls and combined ICP groups (**Fig. 1F** and **Supplementary Table S2**). However, ICP-NoDiab had higher cord BAs than those in the control or ICP-Diab groups. The BA composition of cord plasma was markedly different than maternal plasma, in that the pool was almost entirely composed of conjugated, primary BAs, with unconjugated and secondary species each making up less than 2% of the total pool (**Supplementary Table S2**).

The CA/CDCA ratio was increased threefold in cord plasma from ICP groups compared to controls (**Fig. 1G** and **Supplementary Fig. S1B**). There were no differences in ALT between groups (**Fig. 1H**). FGF19 was highly variable and not significantly different between groups (median [interquartile range] for control and ICP, respectively, were 19.2 [15.8] and 51.9 [28.5] pg/ml, $P = 0.14$).

Glycemic parameters. As a whole group, there were no differences in fasting plasma glucose levels between controls and ICP-Diab or combined ICP groups (**Table 2**). However, there were lower levels of glucose, insulin, C-peptide, and HOMA-IR in ICP-NoDiab compared to ICP-Diab or controls.

Cord plasma glycemic parameters were all substantially lower than maternal parameters (**Table 2**). Moreover, they were similar across groups. The only difference we observed was an increase in the plasma glucose in the ICP-Diab group compared to the ICP-NoDiab group.

Maternal lipid analysis. In maternal plasma, there were no significant differences between groups in total cholesterol, total triglycerides, or free fatty acids (**Fig. 2A-C**). However, ICP-NoDiab subjects had an increase in levels of the ketone body β -hydroxybutyrate (**Fig. 2D**).

Next, we examined lipoprotein distribution by sequential density ultracentrifugation and fast protein liquid chromatography. We found that ICP patients had increased VLDL-cholesterol, which was mostly cholesteryl ester (**Fig. 3A-C, Supplementary Fig. 2A**). ICP subjects also had high LDL-triglycerides (**Fig. 3D, Supplementary Fig. 2B**). ICP-Diab patients also showed elevated VLDL-triglycerides and phospholipids compared to controls (**Fig. 3D-E**). For comparison to prior studies, we also analyzed maternal HDL-cholesterol using a commercial kit relying on precipitation of apoB-containing lipoproteins, then calculated the LDL-cholesterol using the Friedewald formula (58). In this analysis, we observed no significant differences between groups in HDL-cholesterol (mean values 51.8 ± 8.8 , 34.4 ± 6.1 , 33.7 ± 5.2 mg/dl for control, ICP-NoDiab, and ICP-Diab, respectively; all $P > 0.05$) or LDL-cholesterol (mean values 127.0 ± 17.6 , 144.1 ± 9.7 , 184.5 ± 27.5 mg/dl for control, ICP-NoDiab, and ICP-Diab, respectively; all $P > 0.05$).

Cord lipid analysis. Cord plasma lipids were generally lower than those from maternal plasma (**Fig. 2E-H**), as expected (59, 60). Total plasma cholesterol—which arises from delivery of maternal cholesterol across the placenta and *de novo* synthesis in the fetus (61–63)—was not different between groups (**Fig. 2E**). Total triglycerides and free fatty

acids arise from placental transfer of maternal free fatty acids and fatty acids derived from maternal triglyceride-rich remnant particles, as well as *de novo* synthesis (59, 64). We found that cord plasma triglycerides and free fatty acids were two- to three-fold higher in the ICP groups (**Fig. 2F-G**). Ketone bodies are a fuel source and lipogenic precursor in the fetus, but cannot be synthesized by the fetus itself, thus are supplied exclusively by diffusion across the placenta from maternal plasma (60, 61). Consistent with this, we found β -hydroxybutyrate levels were similar in cord and maternal plasma (**Fig. 2H**, compare to Fig. 2D). Compared to controls, β -hydroxybutyrate was higher in the ICP-NoDiab group, and the ICP-Diab group showed a similar trend (**Fig. 2H**). There were no significant differences in these cord lipid parameters between the ICP-NoDiab and ICP-Diab groups.

The distribution of cholesterol across lipoprotein fractions in cord plasma was different than maternal plasma, with substantially more of the cholesterol residing on HDL particles, consistent with prior reports (**Fig. 4A and Supplementary Fig. 2C**) (59). The levels of cholesterol on LDL particles in cord plasma is likely determined by a combination of several pathways: (i) secretion of apoB-containing particles from fetal liver (ii) and placenta (65), (iii) uptake in liver, as LDL-cholesterol levels are tightly inversely correlated with fetal liver LDL receptor (66), and (iv) uptake in adrenals, which convert cholesterol into steroid hormones at a rate 5- to 10-fold higher than in adults (67). HDL particles can be secreted from the fetal-facing membrane of placental trophoblasts, and cholesterol can also be effluxed onto HDL or apoA-I from trophoblasts and from endothelial cells of the fetoplacental vasculature (62, 63, 68). The ICP-Diab group showed higher free cholesterol on VLDL and lower cholesterol and free cholesterol on LDL and HDL, compared to controls, but other cholesterol distribution parameters were not different between groups (**Fig. 4A-C**). Lipoprotein association of triglycerides was also different in cord compared to maternal plasma, with more triglycerides residing on LDL particles (**Fig. 4D and Supplementary Fig. 2D**) (69). We observed no significant differences in triglyceride or phospholipid distribution between groups.

Correlations between BAs and metabolic parameters. We investigated the relationships between maternal BAs and the metabolic features of the mothers that were altered in ICP, using Spearman rank correlations. We found that the maternal CA/CDCA ratio—but not maternal total BAs—was significantly positively correlated with maternal ALT, VLDL-cholesterol, and β -hydroxybutyrate (**Table 3**).

We next investigated the associations of BAs on the cord plasma parameters that were elevated in ICP. We found that the cord CA/CDCA ratio—but not cord total BAs—was positively correlated with cord triglycerides (**Table 3**).

Interestingly, we also found that the maternal CA/CDCA ratio was positively correlated with cord triglycerides and free fatty acids (**Table 3**).

Discussion

The major findings of this work are that ICP is associated—even after UDCA therapy—with (i) higher CA/CDCA ratio in maternal and cord plasma; (ii) a unique maternal dyslipidemia with high cholesterol on VLDL particles and high triglycerides on LDL or remnant particles; (iii) two- to three-fold higher cord triglycerides and free fatty acids; and (iv) a tendency towards higher ketones. Finally, we found that (v) additional diagnosis of gestational diabetes does not strongly further impact the BA and lipid phenotypes of ICP.

An increase in the CA/CDCA ratio has been noted in ICP patients (18, 24, 26–28). Our data suggests that this alteration in BA composition persists after UDCA therapy. The cause of this change is unknown. One potential hypothesis arises from the known accumulation of sulfated progesterone metabolites, which competitively inhibit BAs' ability to activate their receptor FXR (23). This mechanism has been invoked to explain reduced expression of BA transporters (23), which are normally induced by FXR. Another effect of FXR is to suppress the expression of *CYP8B1*, the hepatic enzyme responsible for determining the ratio of CA/CDCA (70). Thus, it is possible that FXR inhibition by sulfated steroid hormones, such as sulfated progesterone metabolites (23) can release this suppression, consequently inducing preferential CA production. FXR also normally suppresses *CYP7A1*, the rate limiting enzyme of BA synthesis (71, 72), but *CYP7A1* activity, as measured by the validated plasma marker of its activity (“C4” or 7 α -hydroxy-4-cholesten-3-one), is actually decreased in ICP patients before and after UDCA treatment (20). Perhaps *CYP8B1* is uniquely regulated by a certain subset of sulfated progesterones, or other steroid hormones altered in ICP (73).

The metabolic sequelae of ICP have received relatively less attention. Prior studies have used chemical precipitation of HDL or LDL particles to report that ICP patients have a tendency towards high total triglycerides, high LDL-cholesterol and low HDL-cholesterol (34–38). On the other hand, other evidence has suggested that cholestasis, including ICP, is associated with accumulation of Lipoprotein X (39, 40). Here, we used ultracentrifugation and size-exclusion chromatography to directly separate lipoproteins by density and particle size. These analyses revealed that ICP is associated with high VLDL-cholesterol, and high triglycerides on particles the size and density of LDL or remnants. This is a unique dyslipidemia, and suggests the possibility that in ICP—potentially through altered steroid hormone or BA signaling—affects either (i) the composition of secreted apoB-containing lipoprotein particles or (ii) the

partitioning of lipoprotein clearance from plasma. It is also possible that ICP and lipoprotein traits have some shared genetic underpinnings, as common variants in several loci achieve genome-wide significance for both (74, 75).

The source of the increased cord plasma triglycerides and free fatty acids is unknown. Because these lipids arise partly from transfer of fatty acids derived from maternal triglyceride-rich lipoproteins across the placenta (59, 64), and the ICP patients showed high LDL-triglycerides, this may suggest a link. Another source of these lipids is from cord *de novo* synthesis (59, 64), partly from ketone body precursors (60, 61). Indeed, the ketone body β -hydroxybutyrate tended to be elevated in ICP patients and cord plasma. This suggests the possibility that alterations in maternal lipid metabolism during ICP may cause the high triglycerides and free fatty acids in cord blood plasma.

BAs regulate multiple aspects of lipid metabolism, and many of these effects occur through activation of the nuclear receptor FXR. This includes the effect of FXR activation to lower plasma triglycerides (76). Studies in mice also demonstrate effects of FXR activation to lower free fatty acids and β -hydroxybutyrate (77). It is of interest whether impaired FXR activity contributes to the lipid phenotypes during ICP. One possibility is impaired activation of FXR due accumulation of sulfated progesterone metabolites, which are elevated in ICP and which are known to competitively inhibit FXR (23). Another possibility is that the change in BA composition, which exists even after treatment, causes differential FXR activity. A robust change in BA composition in ICP, which occurs in maternal and cord blood, is the increase in CA and the CA/CDCA ratio. Because CA is a weaker activator of human FXR compared to CDCA (78–80), it raises the possibility that the elevated CA/CDCA ratio reduces FXR activity in ICP patients. Supporting a possible role for this effect in the lipid phenotypes of ICP, we observed significant correlations between maternal and cord CA/CDCA ratios with plasma lipid levels.

ICP and gestational diabetes may be linked, as women diagnosed with ICP are reported to be at an increased risk of gestational diabetes (33). Prior studies have shown that gestational diabetes is associated with alterations in maternal lipoprotein metabolism, including increased triglycerides and increased levels of small dense LDL (41). Our finding that gestational diabetes did not contribute additional defects in maternal or cord lipids beyond the effects of ICP suggests that either ICP has a more dominant effect on lipid metabolism, or that the defects in lipid metabolism in ICP and gestational diabetes arise from shared mechanisms.

The strengths of this study include: (i) assessment of metabolic parameters in both maternal and cord blood; (ii) the use of additional methods of lipoprotein fractionation by size (liquid chromatography) and density (ultracentrifugation), in comparison to previous publications that used precipitation methods (34, 37, 38); and (iii) inclusion of ICP patients with and without gestational diabetes. Limitations include: (i) small sample size; (ii) cross-sectional design; and (iii) lack of data from ICP patients prior to UDCA treatment.

In this work we established that ICP is linked to alterations in BA composition in maternal and cord blood, which persist after UDCA treatment, despite resolution of the high total BAs and ALT. We hypothesize that the altered CA/CDCA ratio could contribute to lipid alterations, including high levels of triglycerides and free fatty acids in cord blood, and high levels of β -hydroxybutyrate and altered lipoprotein composition in maternal blood. These alterations were correlated to the CA/CDCA ratio, but not total BAs, in both maternal and cord blood plasma. This suggests the possibility that altered BA composition is an underappreciated contributor to the metabolic alterations associated with ICP.

SUPPLEMENTAL MATERIAL

Supplemental Figs. S1 and S2: <https://doi.org/10.6084/m9.figshare.26738695.v2>

Supplemental Tables S1–S3: <https://doi.org/10.6084/m9.figshare.26738695.v2>

Data availability: All source data will be made available upon request to the corresponding author.

Acknowledgements/grant support

This work was supported by funding from the National Institutes of Health R01DK115825, R01DK135298, and R01HL125649 and the Russell Berrie Foundation, and funding from an American Medical Association seed grant (to SGO). This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873 and the National Institute of Diabetes and Digestive and Kidney Diseases, through grants P30DK132710 and P30DK063608. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. **Pataia V, Dixon PH, Williamson C.** Pregnancy and bile acid disorders. *Am J Physiol Gastrointest Liver Physiol* 313: G1–G6, 2017. doi: 10.1152/ajpgi.00028.2017.
2. **Dixon PH, Sambrotta M, Chambers J, Taylor-Harris P, Syngelaki A, Nicolaides K, Knisely AS, Thompson RJ, Williamson C.** An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. *Sci Rep* 7: 11823, 2017. doi: 10.1038/s41598-017-11626-x.
3. **Dixon PH, Wadsworth CA, Chambers J, Donnelly J, Cooley S, Buckley R, Mannino R, Jarvis S, Syngelaki A, Geenes V, Paul P, Sothinathan M, Kubitz R, Lammert F, Tribe RM, Ch'ng CL, Marschall H-U, Glantz A, Khan SA, Nicolaides K, Whittaker J, Geary M, Williamson C.** A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. *Am J Gastroenterol* 109: 76–84, 2014. doi: 10.1038/ajg.2013.406.
4. **Dixon PH, van Mil SWC, Chambers J, Strautnieks S, Thompson RJ, Lammert F, Kubitz R, Keitel V, Glantz A, Mattsson L-A, Marschall H-U, Molokhia M, Moore GE, Linton KJ, Williamson C.** Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. *Gut* 58: 537–544, 2009. doi: 10.1136/gut.2008.159541.
5. **Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nelson-Piercy C, de Swiet M, Warnes G, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C.** Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. *Hum Mol Genet* 9: 1209–1217, 2000.
6. **Painter JN, Savander M, Ropponen A, Nupponen N, Riikonen S, Ylikorkala O, Lehesjoki A-E, Aittomäki K.** Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. *Eur J Hum Genet EJHG* 13: 435–439, 2005. doi: 10.1038/sj.ejhg.5201355.
7. **Müllenbach R, Bennett A, Tetlow N, Patel N, Hamilton G, Cheng F, Chambers J, Howard R, Taylor-Robinson SD, Williamson C.** ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. *Gut* 54: 829–834, 2005. doi: 10.1136/gut.2004.058115.

8. **Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C.** ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. *J Med Genet* 40: e70, 2003.
9. **Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M.** Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. *Lancet Lond Engl* 353: 210–211, 1999. doi: 10.1016/S0140-6736(05)77221-4.
10. **Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G.** Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver* 40: 366–370, 2008. doi: 10.1016/j.dld.2007.10.016.
11. **Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T, van de Vondel P, Sauerbruch T, Reichel C.** Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. *Hepatology* 45: 150–158, 2007. doi: 10.1002/hep.21500.
12. **Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson L-A, Marschall H-U, Lammert F.** Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. *Gut* 56: 265–270, 2007. doi: 10.1136/gut.2006.092742.
13. **Anzivino C, Odoardi MR, Meschiari E, Baldelli E, Facchinetti F, Neri I, Ruggiero G, Zampino R, Bertolotti M, Loria P, Carulli L.** ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver* 45: 226–232, 2013. doi: 10.1016/j.dld.2012.08.011.
14. **Papacleovoulou G, Abu-Hayyeh S, Williamson C.** Nuclear receptor-driven alterations in bile acid and lipid metabolic pathways during gestation. *Biochim Biophys Acta* 1812: 879–887, 2011. doi: 10.1016/j.bbadis.2010.11.001.
15. **Milona A, Owen BM, Cobbold JFL, Willemsen ECL, Cox IJ, Boudjelal M, Cairns W, Schoonjans K, Taylor-Robinson SD, Klomp LWJ, Parker MG, White R, van Mil SWC, Williamson C.** Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function. *Hepatology* 52: 1341–1349, 2010. doi: 10.1002/hep.23849.
16. **Song X, Vasilenko A, Chen Y, Valanejad L, Verma R, Yan B, Deng R.** Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy. *Hepatology* 60: 1993–2007, 2014. doi: 10.1002/hep.27171.
17. **Moscovitz JE, Kong B, Buckley K, Buckley B, Guo GL, Aleksunes LM.** Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064. *Toxicol Appl Pharmacol* 310: 60–67, 2016. doi: 10.1016/j.taap.2016.08.021.
18. **Reyes H, Sjövall J.** Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. *Ann Med* 32: 94–106, 2000.
19. **Abu-Hayyeh S, Ovadia C, Lieu T, Jensen DD, Chambers J, Dixon PH, Lövgren-Sandblom A, Bolier R, Tolenaars D, Kremer AE, Syngelaki A, Noori M, Williams D, Marin JGG, Monte MJ, Nicolaidis KH, Beuers U, Oude-Elferink R, Seed PT, Chappell L, Marschall H-U, Bunnett NW, Williamson C.**

- Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. *Hepatol Baltim Md* 63: 1287–1298, 2016. doi: 10.1002/hep.28265.
20. **Meng L, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta J, Sjoval J.** Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy. *Hepatology* 26: 1573–1579, [date unknown]. doi: 10.1002/hep.510260627.
 21. **Abu-Hayyeh S, Martinez-Becerra P, Sheikh Abdul Kadir SH, Selden C, Romero MR, Rees M, Marschall H-U, Marin JGG, Williamson C.** Inhibition of Na⁺-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. *J Biol Chem* 285: 16504–16512, 2010. doi: 10.1074/jbc.M109.072140.
 22. **Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JGG.** Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. *J Hepatol* 44: 1150–1157, 2006. doi: 10.1016/j.jhep.2005.09.017.
 23. **Abu-Hayyeh S, Papacleovoulou G, Lövgren-Sandblom A, Tahir M, Oduwole O, Jamaludin NA, Ravat S, Nikolova V, Chambers J, Selden C, Rees M, Marschall H-U, Parker MG, Williamson C.** Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. *Hepatol Baltim Md* 57: 716–726, 2013. doi: 10.1002/hep.26055.
 24. **Geenes V, Lövgren-Sandblom A, Benthin L, Lawrance D, Chambers J, Gurung V, Thornton J, Chappell L, Khan E, Dixon P, Marschall H-U, Williamson C.** The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. *PLoS One* 9: e83828, 2014. doi: 10.1371/journal.pone.0083828.
 25. **Laatikainen TJ.** Fetal bile acid levels in pregnancies complicated by maternal intrahepatic cholestasis. *Am J Obstet Gynecol* 122: 852–856, 1975.
 26. **Heikkinen J, Mäentausta O, Ylöstalo P, Jänne O.** Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. *Br J Obstet Gynaecol* 88: 240–245, 1981.
 27. **Brites D, Rodrigues CM, van-Zeller H, Brito A, Silva R.** Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: Portugal. *Eur J Obstet Gynecol Reprod Biol* 80: 31–38, 1998.
 28. **Estiú MC, Monte MJ, Rivas L, Moirón M, Gomez-Rodriguez L, Rodriguez-Bravo T, Marin JGG, Macias RIR.** Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy: Effect of UDCA on intrahepatic cholestasis of pregnancy. *Br J Clin Pharmacol* 79: 316–329, 2015. doi: 10.1111/bcp.12480.
 29. **Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, Nicastrì PL, Locatelli A, Floreani A, Hernandez I, Di Martino V.** Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. *Gastroenterology* 143: 1492–1501, 2012. doi: 10.1053/j.gastro.2012.08.004.
 30. **Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG, PITCH Study Consortium.** Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. *BMJ* 344: e3799, 2012.

31. **Glantz A, Marschall H-U, Lammert F, Mattsson L-A.** Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. *Hepatology* 42: 1399–1405, 2005. doi: 10.1002/hep.20952.
32. **Rodrigues CM, Marín JJ, Brites D.** Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. *Gut* 45: 446–452, 1999.
33. **Martineau M, Raker C, Powrie R, Williamson C.** Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. *Eur J Obstet Gynecol Reprod Biol* 176: 80–85, 2014. doi: 10.1016/j.ejogrb.2013.12.037.
34. **Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM.** Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. *Obstet Gynecol* 107: 106–114, 2006. doi: 10.1097/01.AOG.0000189096.94874.9c.
35. **Hao ZM, Ye YF, Zhang YK, Yang SF, Ye XL.** Lipoprotein lipase and lipid profiles in plasma and placenta from normal pregnancies compared with patients with intrahepatic cholestasis of pregnancy. *Eur J Obstet Gynecol Reprod Biol* 203: 279–285, 2016. doi: 10.1016/j.ejogrb.2016.06.019.
36. **Martineau MG, Raker C, Dixon PH, Chambers J, Machirori M, King NM, Hooks ML, Manoharan R, Chen K, Powrie R, Williamson C.** The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth. *Diabetes Care* 38: 243–248, 2015. doi: 10.2337/dc14-2143.
37. **Nikkilä K, Riikonen S, Lindfors M, Miettinen TA.** Serum squalene and noncholesterol sterols before and after delivery in normal and cholestatic pregnancy. *J Lipid Res* 37: 2687–2695, 1996.
38. **Wojcicka J, Sienko J, Smolarczyk R, Romejko E, Grymowicz M, Czajkowski K.** Alpha-hydroxybutyrate dehydrogenase activity in intrahepatic cholestasis of pregnancy. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet* 89: 247–250, 2005. doi: 10.1016/j.ijgo.2005.02.015.
39. **Fellin R, Manzato E.** Lipoprotein-X fifty years after its original discovery. *Nutr Metab Cardiovasc Dis* 29: 4–8, 2019. doi: 10.1016/j.numecd.2018.09.006.
40. **Heimerl S, Boettcher A, Kaul H, Liebisch G.** Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis. *Biochim Biophys Acta BBA - Mol Cell Biol Lipids* 1861: 681–687, 2016. doi: 10.1016/j.bbalip.2016.04.016.
41. **Barrett HL, Nitert MD, McIntyre HD, Callaway LK.** Normalizing Metabolism in Diabetic Pregnancy: Is It Time to Target Lipids? *Diabetes Care* 37: 1484–1493, 2014. doi: 10.2337/dc13-1934.
42. **Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O.** Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. *BJOG Int J Obstet Gynaecol* 120: 717–723, 2013. doi: 10.1111/1471-0528.12174.
43. **Song F, Chen Y, Chen L, Li H, Cheng X, Wu W.** Association of Elevated Maternal Serum Total Bile Acids With Low Birth Weight and Intrauterine Fetal Growth Restriction. *JAMA Netw Open* 4: e2117409, 2021. doi: 10.1001/jamanetworkopen.2021.17409.
44. **Uyar I, Gülhan I, Öztekin D, Gezer C, Ekin A, Karaca Kurtulmuş S, Özeren M.** Intrahepatic cholestasis of pregnancy may lead to low birth weight. *Turk J Med Sci* 45: 723–728, 2015. doi: 10.3906/sag-1403-7.

45. **Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E, Briz O, Owen BM, Nikolova V, Ovadia C, Huang X, Vaarasmaki M, Baumann M, Jansen E, Albrecht C, Jarvelin M-R, Marin JGG, Knisely AS, Williamson C.** Maternal cholestasis during pregnancy programs metabolic disease in offspring. *J Clin Invest* 123: 3172–3181, 2013. doi: 10.1172/JCI68927.
46. **Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B.** Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 89: 147–91, 2009. doi: 89/1/147 [pii] 10.1152/physrev.00010.2008 [doi].
47. **Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K.** Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* 7: 678–93, 2008. doi: nrd2619 [pii] 10.1038/nrd2619 [doi].
48. **de Aguiar Vallim TQ, Tarling EJ, Edwards PA.** Pleiotropic roles of bile acids in metabolism. *Cell Metab* 17: 657–69, 2013. doi: 10.1016/j.cmet.2013.03.013.
49. **Ahmad TR, Haeusler RA.** Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs. *Nat Rev Endocrinol* 15: 701–712, 2019. doi: 10.1038/s41574-019-0266-7.
50. **Zhong S, Chevre R, Castaño Mayan D, Corliano M, Cochran BJ, Sem KP, van Dijk TH, Peng J, Tan LJ, Hartimath SV, Ramasamy B, Cheng P, Groen AK, Kuipers F, Goggi JL, Drum C, van Dam RM, Tan R-S, Rye K-A, Hayden MR, Cheng C-Y, Chacko S, Flannick J, Sim X, Tan HC, Singaraja RR.** Haploinsufficiency for CYP8B1 associates with increased insulin sensitivity in humans. .
51. **Arterburn DE, Courcoulas AP.** Bariatric surgery for obesity and metabolic conditions in adults. *BMJ* 349: g3961, 2014.
52. **Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB.** Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. *Obes Silver Spring* 17: 1671–7, 2009. doi: oby2009102 [pii] 10.1038/oby.2009.102 [doi].
53. **Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H.** Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. *Metabolism* 58: 1400–7, 2009. doi: 10.1016/j.metabol.2009.05.006.
54. **Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S.** Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. *J Clin Endocrinol Metab* 98: E708-12, 2013. doi: 10.1210/jc.2012-3736.
55. **Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J, Strodel WE, Still CD, Argyropoulos G.** A Role for Fibroblast Growth Factor 19 and Bile Acids in Diabetes Remission After Roux-en-Y Gastric Bypass. *Diabetes Care* 36: 1859–64, 2013. doi: 10.2337/dc12-2255.
56. **Ferrannini E, Camastra S, Astiarraga B, Nannipieri M, Castro-Perez J, Xie D, Wang L, Chakravarthy M, Haeusler RA.** Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. *Diabetes* 64: 3377–85, 2015. doi: 10.2337/db15-0214.
57. **Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C.** Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. *Hepatology* 59: 1482–1491, 2014. doi: 10.1002/hep.26617.

58. **Friedewald WT, Levy RI, Fredrickson DS.** Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. *Clin Chem* 18: 499–502, 1972.
59. **Bansal N, Cruickshank JK, McElduff P, Durrington PN.** Cord blood lipoproteins and prenatal influences. *Curr Opin Lipidol* 16: 400–408, 2005.
60. **Herrera E.** Metabolic adaptations in pregnancy and their implications for the availability of substrates to the fetus. *Eur J Clin Nutr* 54 Suppl 1: S47-51, 2000.
61. **Herrera E.** Lipid metabolism in pregnancy and its consequences in the fetus and newborn. *Endocrine* 19: 43–55, 2002. doi: 10.1385/ENDO:19:1:43.
62. **Palinski W.** Maternal-Fetal cholesterol transport in the placenta: good, bad, and target for modulation. *Circ Res* 104: 569–571, 2009. doi: 10.1161/CIRCRESAHA.109.194191.
63. **Woollett LA.** Maternal cholesterol in Fetal development: transport of cholesterol from the maternal to the fetal circulation. *Am J Clin Nutr* 82: 1155–1161, 2005. doi: 10.1093/ajcn/82.6.1155.
64. **Rebholz SL, Burke KT, Yang Q, Tso P, Woollett LA.** Dietary fat impacts fetal growth and metabolism: uptake of chylomicron remnant core lipids by the placenta. *Am J Physiol Endocrinol Metab* 301: E416-425, 2011. doi: 10.1152/ajpendo.00619.2010.
65. **Madsen EM, Lindegaard MLS, Andersen CB, Damm P, Nielsen LB.** Human placenta secretes apolipoprotein B-100-containing lipoproteins. *J Biol Chem* 279: 55271–55276, 2004. doi: 10.1074/jbc.M411404200.
66. **Cai HJ, Xie CL, Chen Q, Chen XY, Chen YH.** The relationship between hepatic low-density lipoprotein receptor activity and serum cholesterol level in the human fetus. *Hepatol Baltim Md* 13: 852–857, 1991.
67. **Carr BR, Simpson ER.** Lipoprotein utilization and cholesterol synthesis by the human fetal adrenal gland. *Endocr Rev* 2: 306–326, 1981. doi: 10.1210/edrv-2-3-306.
68. **Stefulj J, Panzenboeck U, Becker T, Hirschmugl B, Schweinzer C, Lang I, Marsche G, Sadjak A, Lang U, Desoye G, Wadsack C.** Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. *Circ Res* 104: 600–608, 2009. doi: 10.1161/CIRCRESAHA.108.185066.
69. **Yonezawa R, Okada T, Kitamura T, Fujita H, Inami I, Makimoto M, Hosono S, Minato M, Takahashi S, Mugishima H, Yamamoto T, Masaoka N.** Very low-density lipoprotein in the cord blood of preterm neonates. *Metabolism* 58: 704–707, 2009. doi: 10.1016/j.metabol.2009.02.004.
70. **Chiang JY.** Recent advances in understanding bile acid homeostasis. *F1000Research* 6: 2029, 2017. doi: 10.12688/f1000research.12449.1.
71. **Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ.** Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. *Mol Cell* 6: 507–15, 2000. doi: S1097-2765(00)00050-2 [pii].
72. **Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA.** A regulatory cascade of the nuclear receptors FXR,

SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell* 6: 517–26, 2000. doi: S1097-2765(00)00051-4 [pii].

73. Pařízek A, Hill M, Dušková M, Vitek L, Velíková M, Kancheva R, Šimják P, Koucký M, Kokrdová Z, Adamcová K, Černý A, Hájek Z, Stárka L. A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy. *PloS One* 11: e0159203, 2016. doi: 10.1371/journal.pone.0159203.
74. Dixon PH, Levine AP, Cebola I, Chan MMY, Amin AS, Aich A, Mozere M, Maude H, Mitchell AL, Zhang J, Chambers J, Syngelaki A, Donnelly J, Cooley S, Geary M, Nicolaides K, Thorsell M, Hague WM, Estiu MC, Marschall H-U, Gale DP, Williamson C. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements. *Nat Commun* 13: 4840, 2022. doi: 10.1038/s41467-022-29931-z.
75. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon DR, DuVall SL, Li J, Peloso GM, Chaffin M, Small AM, Huang J, Tang H, Lynch JA, Ho Y-L, Liu DJ, Emdin CA, Li AH, Huffman JE, Lee JS, Natarajan P, Chowdhury R, Saleheen D, Vujkovic M, Baras A, Pyarajan S, Di Angelantonio E, Neale BM, Naheed A, Khera AV, Danesh J, Chang K-M, Abecasis G, Willer C, Dewey FE, Carey DJ, Global Lipids Genetics Consortium, Myocardial Infarction Genetics (MIGen) Consortium, Geisinger-Regeneron DiscovEHR Collaboration, VA Million Veteran Program, Concato J, Gaziano JM, O'Donnell CJ, Tsao PS, Kathiresan S, Rader DJ, Wilson PWF, Assimes TL. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat Genet* 50: 1514–1523, 2018. doi: 10.1038/s41588-018-0222-9.
76. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. *J Lipid Res* 53: 1723–37, 2012. doi: jlr.R024794 [pii] 10.1194/jlr.R024794 [doi].
77. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc Natl Acad Sci U A* 103: 1006–11, 2006. doi: 0506982103 [pii] 10.1073/pnas.0506982103 [doi].
78. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. *Science* 284: 1362–5, 1999.
79. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. *Science* 284: 1365–8, 1999.
80. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 3: 543–53, 1999. doi: S1097-2765(00)80348-2 [pii].

Table 1. Patient characteristics.

	Control	ICP-all	ICP-NoDiab	ICP-Diab
N	7	12	6	6
Maternal age (years)	34.1 ± 1.3	32.4 ± 2.3	30.2 ± 3.5	34.7 ± 2.8
BMI (kg/m²) †	26.6 ± 2.1	28.4 ± 2.0		
Highest total BAs–ARUP labs (μmol/l)	-	56 [36.7]	42 [39.3]	59.9 [33.5]
# patients with BAs–ARUP labs >40 μmol/l	-	7 (58%)	3 (50%)	4 (67%)
Highest ALT–ARUP labs (IU/l)	-	123 [267.5]	120.5 [200]	124 [326]
GA at initiation of UDCA therapy (wks)	-	34.2 ± 0.7	33.9 ± 0.8	34.5 ± 1.1
GA at maternal blood collection (wks)	36.6 ± 0.2	36.6 ± 0.1	36.7 ± 0.2	36.4 ± 0.2
GA at delivery (wks)	37.0 ± 0.1	37.3 ± 0.2	37.2 ± 0.1	37.5 ± 0.3
Birthweight (g)	2827 ± 94	3068 ± 147	3095 ± 278	3040 ± 132

†BMI was available for 6/7 controls and 7/12 ICP patients and was determined at GA 10.0 ± 1.5 weeks. Data is presented as the median ± [interquartile range].

Abbreviations: ALT=alanine aminotransferase; BMI=body mass index; GA=gestational age

Table 2. Glycemic parameters.

	Median [IQR]				P value			
	Control	ICP- all	ICP- NoDiab	ICP- Diab	ICP- all vs. control	ICP- NoDiab vs. control	ICP-Diab vs. control	ICP-Diab vs. ICP-NoDiab
<u>Maternal</u>								
Fasting plasma glucose (mg/dl)	87.3 [8.2]	81.5 [26.6]	54.1 [25.7]	87.0 [6.7]	0.254	0.010*	0.416	0.006**
Insulin (mU/l)	9.6 [8.3]	5.1 [6.4]	3.2 [0.1]	10.2 [18.4]	0.326	0.018*	0.389	0.009**
C-peptide (nmol/l)	1.18 [0.73]	0.95 [1.16]	0.39 [0.37]	1.74 [1.88]	1.000	0.115	0.115	0.008**
HOMA-IR	2.14 [1.60]	0.94 [1.55]	0.52 [0.20]	2.36 [4.07]	0.207	0.007**	0.444	0.004**
<u>Cord</u>								
Glucose (mg/dl)	71.9 [17.6]	71.4 [23.4]	61.0 [11.4]	75.5 [22.3]	0.913	0.206	0.104	0.016*
Insulin (mU/l)	4.9 [6.8]	3.7 [4.0]	2.7 [2.4]	6.3 [5.0]	0.679	0.234	0.493	0.253
C-peptide (nmol/l)	0.19 [0.09]	0.23 [0.19]	0.21 [0.10]	0.28 [0.26]	0.777	0.418	0.345	0.418

Data is presented as the median [interquartile range]. All ICP subjects were treated with UDCA in this study.

*P<0.05, **P<0.01

Table 3. Spearman rank correlations. Correlations between the metabolic parameters that were altered in ICP, and total BAs or the CA/CDCA ratio.

BA parameter	Metabolic parameter	All	
		R _s	P
Maternal BAs–maternal metabolites			
Total BAs	ALT	0.35	0.163
Total BAs	VLDL-cholesterol	0.26	0.322
Total BAs	LDL-triglyceride	-0.11	0.676
Total BAs	βOH butyrate	0.26	0.308
CA/CDCA	ALT	0.78	0.0002***
CA/CDCA	VLDL-cholesterol	0.51	0.046*
CA/CDCA	LDL-triglyceride	0.26	0.332
CA/CDCA	βOH butyrate	0.60	0.011*
Cord BAs–cord metabolites			
Total BAs	Triglyceride	0.42	0.108
Total BAs	Free fatty acids	0.35	0.183
Total BAs	βOH butyrate	0.21	0.437
CA/CDCA	Triglyceride	0.62	0.010*
CA/CDCA	Free fatty acids	0.44	0.085
CA/CDCA	βOH butyrate	0.07	0.807
Maternal BAs–cord metabolites			
Total BAs	Triglyceride	0.48	0.058
Total BAs	Free fatty acids	0.09	0.740
Total BAs	βOH butyrate	0.03	0.901
CA/CDCA	Triglyceride	0.61	0.012*
CA/CDCA	Free fatty acids	0.56	0.023*
CA/CDCA	βOH butyrate	0.35	0.185

*P<0.05, ***P<0.001

Figure legends

Figure 1. Bile acid levels and composition. (A-B) Total plasma BAs and ALT in ICP-diagnosed individuals at the time of diagnosis and initiation of UDCA treatment, and ~2.7 weeks later, at the time of fasting maternal blood collection for full analysis. The red lines represent the ICP-Diab group and the black lines represent the ICP-NoDiab group. (C) Total fasting plasma BAs in all maternal subjects at the time of maternal blood collection. (D) Ratio of cholic acid (CA) and its conjugated forms to chenodeoxycholic acid (CDCA) and its conjugated forms. (E) Plasma ALT in all maternal subjects at the time of maternal blood collection. (F) Total BAs in cord blood plasma. (G) Ratio of CA and its conjugated forms to CDCA and its conjugated forms, in cord blood plasma. (H) ALT in cord blood plasma. Data show mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ for ICP-all (n=12) versus controls (n=7) by Wilcoxon signed rank test (for panels A-B) or Mann-Whitney test (for panels C-H). $^{\$}P < 0.05$, $^{\$\$}P < 0.01$ for ICP-NoDiab (n=6) or ICP-Diab (n=6) versus controls (n=7) and $^{\&}P < 0.05$ for ICP-Diab (n=6) versus ICP-NoDiab (n=7) by Kruskal-Wallis test with posthoc Dunn tests.

Figure 2. Total plasma lipids. (A) Total cholesterol, (B) total triglycerides, (C) free fatty acids, and (D) β -hydroxybutyrate in maternal plasma. (E) Total cholesterol, (F) total triglycerides, (G) free fatty acids, and (H) β -hydroxybutyrate in cord blood plasma. The box plot shows the distribution of the dataset with a focus on the median value * $P < 0.05$ for ICP-all (n=12) versus controls (n=7) by Mann-Whitney test. $^{\$}P < 0.05$, $^{\$\$}P < 0.01$ for ICP-NoDiab (n=6) or ICP-Diab (n=6) versus controls (n=7) by Kruskal-Wallis test with posthoc Dunn tests.

Figure 3. Lipids in fractionated maternal plasma. (A-E) Very-low-density lipoprotein (VLDL) ($d < 1.006$), low-density lipoprotein (LDL) ($1.006 < d < 1.063$), and high-density lipoprotein (HDL) ($1.063 < d < 1.210$) fractionated by sequential density ultracentrifugation. (A) C=cholesterol, (B) CE=cholesteryl ester, (C) FC=free cholesterol, (D) TG=triglycerides, (E) PL=phospholipid. The box plot shows the distribution of the dataset and the line within the box represents the median value ** $P < 0.01$ for ICP-all (n=12) versus controls (n=7) by Mann-Whitney test. $^{\$}P < 0.05$, $^{\$\$}P < 0.01$ for ICP-NoDiab (n=6) or ICP-Diab (n=6) versus controls (n=7) by Kruskal-Wallis test with posthoc Dunn tests.

Figure 4. Lipids in fractionated cord blood plasma. (A-E) VLDL ($d < 1.006$), LDL ($1.006 < d < 1.063$), and HDL ($1.063 < d < 1.210$) fractionated by sequential density ultracentrifugation. (A) C=cholesterol, (B) CE=cholesteryl ester, (C) FC=free cholesterol, (D) TG=triglycerides, (E) PL=phospholipid. The box plot shows the distribution of the dataset and the line within the box represents the median value. ^sP<0.05 for ICP-NoDiab (n=6) or ICP-Diab (n=6) versus controls (n=7) and [&]P<0.05 for ICP-Diab versus ICP-NoDiab by Kruskal-Wallis test with posthoc Dunn tests.




Figure 1




Figure 2




Figure 3




Figure 4